Biotech Values

[DewDiligence]

[MNTA] Copaxone Sales Keep Growing

2Q08 US Copaxone sales rose 17%, year-over-year, to $332M (a $1.33B annualized rate), the highest quarterly total ever. Ex-US Copaxone sales rose much more sharply (+53%) due in part to the weak dollar.

For now, the US sales number is the most pertinent one for MNTA insofar as the US is the only market to date in which MNTA and partner, Sandoz, have submitted an application to market a generic version of Copaxone.

http://biz.yahoo.com/bw/080729/20080728006442.html

Annualized 2Q08 Sales
(as reported by Teva):

US: $1.33B (59% of total), +17% YoY, +7% QoQ
ex-US: $924M (41% of total), +53% YoY, +0% QoQ
===
Total: $2.25B, +29% YoY, +4% QoQ